This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.
At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license
Chinese pharma BeiGene also owns the rights to Zanidatamab and ZW49 in a number of East Asian countries including China and South Korea as well as Australia and New Zealand.
Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).
The milestone was achieved thanks to Boehringer’s collaboration with Chinese pharma company BeiGene, which included Boehringer offering manufacturing capabilities to support the launch of its monoclonal antibody tislelizumab. ... Boehringer will
Although, BeiGene has said that Brukinsa demonstrated numerically higher VGPR rates, and improvements in safety and tolerability compared to Imbruvica. ... meaningful responses for many patients,” said Jane Huang (pictured left), chief medical officer,
However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib).
More from news
Approximately 11 fully matching, plus 8 partially matching documents found.
BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.
More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.
EMA gains a new executive director, Gilead appoints a new senior vice president and BeiGene hires a new chief business exec. ... BeiGene. BeiGene has appointed Angus Grant (pictured above) as chief business executive.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...